Lupvindol Biosciences partners with Splash Beverage Group partners to develop veterinary cannabis-based drugs for canine cancer and pain

Splash Beverage Group collaborates with Lupvindol Biosciences to develop CannEpil as a veterinary drug targeting canine oncology and chronic pain, marking a shift from beverages to cannabinoid-based pharmaceuticals.

Splash Beverage Group has said it is teaming up with Lupvindol Biosciences to develop CannEpil as a veterinary drug candidate, starting with canine oncology and chronic pain. The company said the work will run through the US Food and Drug Administration’s veterinary channel, beginning with the Investigational New Animal Drug process and, potentially, conditional approval.

Under the agreement, Lupvindol will handle the scientific and regulatory work, while Splash will provide staged funding and oversee commercial planning. Splash said it will keep ownership of the data, submissions and intellectual property created through the programme, a structure that appears designed to limit capital outlay while preserving upside if the asset advances.

The move extends Splash’s broader shift away from beverages and towards cannabinoid-based pharmaceuticals. Earlier disclosures reported by Nasdaq described its acquisition of exclusive global rights to CannEpil, originally developed for drug-resistant epilepsy and already available in some overseas markets under EU manufacturing standards.

The new veterinary focus comes with material execution risk. Splash acknowledged that CannEpil has not been approved for animal use in the US, and that development will depend on FDA feedback, study outcomes and funding. Even so, the company is trying to position the asset as a platform play in a market where it says companion-animal cancer and pain remain under-served.